Viatris Inc (VTRS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Viatris Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Viatris Inc's ROI in the second quarter of 2026?
Viatris Inc recorded a cumulative net loss of $-411 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -1.37%.
Within the Healthcare sector 127 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 1679 to 2608.
PITTSBURGH, April 15, 2024 - Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today the appointment of Corinne Le Goff as Chief Commercial Officer. Le Goff will also join the esteemed Executive Leadership Team of the company, effective immediately. This strategic move aims to leverage Le Goff s extensive industry experience and expertise, positioning Viatris Inc. for continued growth and success. Corinne Le Goff brings with her a strong track record of delivering exceptional results in the pharmaceutical and healthcare sectors. With an unrivaled understanding of market dynamics and customer needs, she has consistently demonstrated the ability to drive revenue growth and develop innovative commercial strategies. As Viatris Inc. s new Chief Commercial Officer, Le Goff will be responsible for overseeing the company s global commercial operations, including sales, marketing, and market access.
PITTSBURGH, Dec. 15, 2023 - Viatris Inc. (NASDAQ: VTRS), a global healthcare company, publicly disclosed its preparations for Phase 2 of its strategic plan by appointing Theodora Doretta Mistras as Chief Financial Officer and Philippe Martin as Chief RandD Officer. Mistras is set to assume the role on March 1, 2024, joining Viatris after a successful career in the finance industry. Martin, with extensive experience in research and development, will also take on his new position at the same time. The company expressed its appreciation to Sanjeev Narula for his instrumental role in the successful execution of Viatris Phase 1 strategy. Narula will assist in ensuring a smooth transition for the incoming CFO before his departure on March 1, 2024.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
